Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.[1]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | IGF1R, ErbB3 |
Clinical data | |
Other names | MM-141 |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C8802H13532N2392O2796S58 |
Molar mass | 199458.51 g·mol−1 |
It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.[2]
{{cite web}}
: CS1 maint: numeric names: authors list (link)